EyePoint Pharmaceuticals Announces Board and CFO Changes
Ticker: EYPT · Form: 8-K · Filed: Jun 21, 2024 · CIK: 1314102
| Field | Detail |
|---|---|
| Company | Eyepoint Pharmaceuticals, Inc. (EYPT) |
| Form Type | 8-K |
| Filed Date | Jun 21, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $850,000, $1,100,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, board-election, cfo-appointment
TL;DR
EyePoint Pharma shakes up board, names new CFO.
AI Summary
On June 20, 2024, EyePoint Pharmaceuticals, Inc. filed an 8-K report detailing several key events. The company announced the election of new directors, including Dr. Peter S. Arduini and Ms. Jennifer L. Chien, and the appointment of Ms. Chien as Chief Financial Officer. Additionally, the report covers the departure of certain officers and changes to compensatory arrangements.
Why It Matters
Changes in board composition and executive leadership, particularly the CFO role, can signal strategic shifts and impact investor confidence.
Risk Assessment
Risk Level: medium — Changes in executive leadership and board composition can indicate internal shifts that may affect future performance.
Key Numbers
- 20240620 — Date of Earliest Event Reported (Indicates the effective date of the reported changes.)
Key Players & Entities
- EyePoint Pharmaceuticals, Inc. (company) — Registrant
- Dr. Peter S. Arduini (person) — Elected Director
- Ms. Jennifer L. Chien (person) — Elected Director and Appointed CFO
- pSivida Corp. (company) — Former Company Name
- pSivida LTD (company) — Former Company Name
FAQ
Who were the newly elected directors?
Dr. Peter S. Arduini and Ms. Jennifer L. Chien were elected as directors.
What is Ms. Jennifer L. Chien's new role?
Ms. Jennifer L. Chien was appointed as the Chief Financial Officer.
What is the exact date of the earliest event reported in this filing?
The earliest event reported is dated June 20, 2024.
What was EyePoint Pharmaceuticals' former name?
EyePoint Pharmaceuticals was formerly known as pSivida Corp. and pSivida LTD.
What items are covered in this 8-K filing?
This filing covers the departure of directors or certain officers, election of directors, appointment of certain officers, compensatory arrangements, submission of matters to a vote of security holders, and financial statements and exhibits.
Filing Stats: 1,227 words · 5 min read · ~4 pages · Grade level 10.3 · Accepted 2024-06-21 07:05:38
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 EYPT The Nasdaq Global Market Ind
- $850,000 — compensation limit contained therein to $850,000 for ongoing directors in any calendar y
- $1,100,000 — oing directors in any calendar year and $1,100,000 for new directors in any calendar year.
Filing Documents
- eypt-20240621.htm (8-K) — 125KB
- eypt-ex10_1.htm (EX-10.1) — 109KB
- eypt-ex10_2.htm (EX-10.2) — 161KB
- 0000950170-24-075872.txt ( ) — 550KB
- eypt-20240621.xsd (EX-101.SCH) — 23KB
- eypt-20240621_htm.xml (XML) — 4KB
07 Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders. On April 23, 2024, the record date for the Annual Meeting, there were 52,084,148 shares of Common Stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 46,400,436 or 89.09%, were present in person via virtual communication or voted by proxy, which constituted a quorum. Each stockholder is entitled to one vote for each share held and cumulative voting for directors is not permitted. The final results of the voting for each matter submitted to a vote of stockholders at the meeting are as follows: Proposal No. 1. Election of Directors The Company's stockholders elected the following directors to the Board, each to serve until the Company's 2024 Annual Meeting of Stockholders or until such person's successor is duly elected and qualified. The voting on this proposal is set forth below: Vote Type Vote Results Gran Ando, M.D. For 34,332,943 Withheld 10,073,449 Broker Non-Votes 1,994,044 Jay S. Duker, M.D. For 44,076,361 Withheld 330,031 Broker Non-Votes 1,994,044 Nancy Lurker For 43,072,470 Withheld 1,333,922 Broker Non-Votes 1,994,044 John B. Landis, Ph.D. For 43,086,644 Withheld 1,319,748 Broker Non-Votes 1,994,044 David Guyer, M.D. For 43,708,357 Withheld 698,035 Broker Non-Votes 1,994,044 Wendy F. DiCicco For 43,721,247 Withheld 685,145 Broker Non-Votes 1,994,044 Anthony P. Adamis, M.D. For 44,036,082 Withheld 370,310 Broker Non-Votes 1,994,044 Karen Zaderej For 44,034,115 Withheld 372,277 Broker Non-Votes 1,994,044 Stuart Duty For 44,065,948 Withheld 340,444 Broker Non-Votes 1,994,044 Proposal No. 2. Amendment to 2023 Long-Term Incentive Plan The Company's stockholders approved the 2023 Plan Amendment to (i) increase the number of shares of Common Stock authorized for issuance thereunder by 4,000,000 shares and (i
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 10.1 EyePoint Pharmaceuticals, Inc. Amendment No 1. to 2023 Long-Term Incentive Plan. 10.2 EyePoint Pharmaceuticals, Inc. Amendment No 2. to 2019 Employee Stock Purchase Plan 104 Cover Page Interactive Data File (embedded within the inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EYEPOINT PHARMACEUTICALS, INC. Date: June 21, 2024 By: /s/ George O. Elston George O. Elston Executive Vice President and Chief Financial Officer